[go: up one dir, main page]

NO328738B1 - Anvendelse av RAR-agonist for fremstilling av medikamenter. - Google Patents

Anvendelse av RAR-agonist for fremstilling av medikamenter. Download PDF

Info

Publication number
NO328738B1
NO328738B1 NO20021823A NO20021823A NO328738B1 NO 328738 B1 NO328738 B1 NO 328738B1 NO 20021823 A NO20021823 A NO 20021823A NO 20021823 A NO20021823 A NO 20021823A NO 328738 B1 NO328738 B1 NO 328738B1
Authority
NO
Norway
Prior art keywords
rarγ
selective
agonist
rar
lung
Prior art date
Application number
NO20021823A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021823D0 (no
NO20021823L (no
Inventor
Paula Nanette Belloni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20021823D0 publication Critical patent/NO20021823D0/no
Publication of NO20021823L publication Critical patent/NO20021823L/no
Publication of NO328738B1 publication Critical patent/NO328738B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20021823A 1999-10-19 2002-04-18 Anvendelse av RAR-agonist for fremstilling av medikamenter. NO328738B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16041599P 1999-10-19 1999-10-19
PCT/EP2000/010076 WO2001030326A1 (en) 1999-10-19 2000-10-13 Treatment of emphysema using rar selective retinoid agonists

Publications (3)

Publication Number Publication Date
NO20021823D0 NO20021823D0 (no) 2002-04-18
NO20021823L NO20021823L (no) 2002-04-18
NO328738B1 true NO328738B1 (no) 2010-05-03

Family

ID=22576814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021823A NO328738B1 (no) 1999-10-19 2002-04-18 Anvendelse av RAR-agonist for fremstilling av medikamenter.

Country Status (33)

Country Link
US (1) US6300350B1 (es)
EP (1) EP1225878B1 (es)
JP (2) JP4074458B2 (es)
KR (1) KR100485581B1 (es)
CN (1) CN1201730C (es)
AR (1) AR029648A1 (es)
AT (1) ATE344661T1 (es)
AU (1) AU777325B2 (es)
BR (1) BR0015225A (es)
CA (1) CA2387844C (es)
CY (1) CY1105941T1 (es)
CZ (1) CZ20021657A3 (es)
DE (1) DE60031790T2 (es)
DK (1) DK1225878T3 (es)
ES (1) ES2274810T3 (es)
HR (1) HRP20020329A2 (es)
HU (1) HUP0203295A3 (es)
IL (1) IL149151A0 (es)
JO (1) JO2178B1 (es)
MA (1) MA26835A1 (es)
MX (1) MXPA02003843A (es)
MY (1) MY129001A (es)
NO (1) NO328738B1 (es)
NZ (1) NZ518118A (es)
PE (1) PE20010678A1 (es)
PL (1) PL357499A1 (es)
PT (1) PT1225878E (es)
RS (1) RS50165B (es)
RU (1) RU2257383C2 (es)
TR (1) TR200201071T2 (es)
TW (1) TWI288639B (es)
WO (1) WO2001030326A1 (es)
ZA (1) ZA200202576B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
CA2458266C (en) 2001-09-18 2011-03-15 F. Hoffmann-La Roche Ag Substituted urea retinoid agonists ii
RU2299877C2 (ru) * 2001-09-18 2007-05-27 Ф.Хоффманн-Ля Рош Аг Производные алкилмочевины, обладающие свойствами ретиноидных агонистов (i), фармацевтическая композиция и лекарственное средство
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
JP4926707B2 (ja) 2003-08-22 2012-05-09 ダニスコ エイ／エス 封入化抗菌材料
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
EP2089017A2 (en) * 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
DK3721880T3 (da) 2010-09-01 2022-05-09 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og regenerering
ES2759584T3 (es) 2011-06-24 2020-05-11 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
WO2013019626A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
US9963439B2 (en) 2013-08-20 2018-05-08 University Of Washington Through Its Center For Commercialization Specific inhibitors of cytochrome P450 26 retinoic acid hydroxylase
WO2015041809A2 (en) 2013-08-26 2015-03-26 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
PL181385B1 (pl) * 1993-08-19 2001-07-31 Janssen Pharmaceutica Nv Nowe pochodne dihydrobenzopiranu o wlasciwosciach naczyniozwezajacych, kompozycja farmaceutyczna i sposób wytwarzania pochodnych dihydrobenzopiranu PL PL PL PL PL PL
CA2129773C (en) * 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
DK0728742T3 (da) * 1995-02-24 2000-04-17 Hoffmann La Roche Hidtil ukendte retinoider
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
TW418186B (en) * 1995-06-05 2001-01-11 Bristol Myers Squibb Co Retinoid-like compounds
US5624957A (en) * 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
JP3704471B2 (ja) * 1997-11-12 2005-10-12 エフ．ホフマン−ラ ロシュ アーゲー レチノイド拮抗薬を用いるヘルパーｔ細胞媒介性免疫疾患の処置
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
AU4222400A (en) 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
AU4228000A (en) * 1999-04-14 2000-11-14 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease
WO2000061232A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
DK1206436T3 (da) * 1999-08-02 2005-02-14 Hoffmann La Roche Retinoider til behandling af emfysem
US6479670B1 (en) * 1999-08-25 2002-11-12 Hoffmann-La Roche Inc. Selective retinoid acid receptor agonists

Also Published As

Publication number Publication date
WO2001030326A1 (en) 2001-05-03
EP1225878A1 (en) 2002-07-31
JO2178B1 (en) 2003-04-23
CZ20021657A3 (cs) 2002-10-16
ES2274810T3 (es) 2007-06-01
PE20010678A1 (es) 2001-07-04
NZ518118A (en) 2004-02-27
AU777325B2 (en) 2004-10-14
HK1051002A1 (zh) 2003-07-18
ATE344661T1 (de) 2006-11-15
NO20021823D0 (no) 2002-04-18
JP4850791B2 (ja) 2012-01-11
ZA200202576B (en) 2003-09-23
HUP0203295A2 (hu) 2003-01-28
IL149151A0 (en) 2002-11-10
DE60031790D1 (de) 2006-12-21
DE60031790T2 (de) 2007-09-20
TR200201071T2 (tr) 2002-08-21
BR0015225A (pt) 2002-07-16
AR029648A1 (es) 2003-07-10
YU29002A (sh) 2005-06-10
MXPA02003843A (es) 2002-09-30
RU2257383C2 (ru) 2005-07-27
CY1105941T1 (el) 2011-04-06
HRP20020329A2 (en) 2004-04-30
EP1225878B1 (en) 2006-11-08
JP4074458B2 (ja) 2008-04-09
DK1225878T3 (da) 2007-03-05
CN1201730C (zh) 2005-05-18
KR20020043640A (ko) 2002-06-10
US6300350B1 (en) 2001-10-09
JP2007302689A (ja) 2007-11-22
CA2387844C (en) 2009-04-14
HUP0203295A3 (en) 2003-04-28
AU1137401A (en) 2001-05-08
JP2003512418A (ja) 2003-04-02
NO20021823L (no) 2002-04-18
RS50165B (sr) 2009-05-06
PT1225878E (pt) 2007-01-31
TWI288639B (en) 2007-10-21
KR100485581B1 (ko) 2005-04-27
PL357499A1 (pl) 2004-07-26
CN1382042A (zh) 2002-11-27
MA26835A1 (fr) 2004-12-20
CA2387844A1 (en) 2001-05-03
MY129001A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
JP4850791B2 (ja) Ｒａｒ選択的レチノイド拮抗薬を用いた気腫の治療
CN113840598B (zh) 大麻素酸酯组合物及其用途
WO2013138744A1 (en) Compositions for the treatment of skin disorders
CN102579432B (zh) 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的应用
JP2019504819A (ja) 心臓肥大および肺高血圧の治療用医薬の製造におけるカウラン化合物の使用
US20020049252A1 (en) Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid
EA027524B1 (ru) Способ ингибирования гиперпроницаемости сосудов при отеке маклы
CA2321935A1 (en) Use of alpha-rar antagonists for inhibition of mucin secretion
IL92238A (en) ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
WO1999052532A1 (en) Method for reducing central nervous system impairment
WO2000038670A1 (en) Propanolol metabolites useful for antioxidant activities
Lau et al. Synergistic potentiation by captopril and propranolol of bradykinin‐induced bronchoconstriction in the Guinea‐pig
US20050209204A1 (en) Treatment of age-related lung abnormalities using estrogen and/or retinoids
CN104188945A (zh) 辅酶q10及其组合物在制备防护吸烟致肺损伤的保健食品及药品方面的应用
Burstein Prostaglandins and Cannabis—IV: A Biochemical Basis for Therapeutic Applications
MXPA00008580A (es) Uso de antagonistas del rar alfa para la inhibicion de la produccion de mucina
US20120295982A1 (en) Treating human male copd patients with oral bedoradrine
HK40063789A (en) Cannabinoid acid ester compositions and uses thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees